Abstract
Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.
| Original language | English |
|---|---|
| Pages (from-to) | 702-705 |
| Number of pages | 4 |
| Journal | Journal of Microbiology and Biotechnology |
| Volume | 12 |
| Issue number | 4 |
| Publication status | Published - 2002 Aug 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Applied Microbiology and Biotechnology
Cite this
}
Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis. / Kwon, Ho Jeong; Kim, Dong Hoon; Shim, Joong Sub; Ahn, Jong Woong.
In: Journal of Microbiology and Biotechnology, Vol. 12, No. 4, 01.08.2002, p. 702-705.Research output: Contribution to journal › Article
TY - JOUR
T1 - Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis
AU - Kwon, Ho Jeong
AU - Kim, Dong Hoon
AU - Shim, Joong Sub
AU - Ahn, Jong Woong
PY - 2002/8/1
Y1 - 2002/8/1
N2 - Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.
AB - Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.
UR - http://www.scopus.com/inward/record.url?scp=0036694418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036694418&partnerID=8YFLogxK
M3 - Article
VL - 12
SP - 702
EP - 705
JO - Journal of Microbiology and Biotechnology
JF - Journal of Microbiology and Biotechnology
SN - 1017-7825
IS - 4
ER -